Explanation
Adverseeventsprofle
IntheuK.theMedicinesandHealthcareProductsReaulatorv Aqencv MHRA and theCommissiononluman
MedicinesCHM) iointly operatetheellow Card Schemewhichhiahliahtssuspected probemsor incidents
suchasadversedruareactions.Thisschemeisimoortantasoftendruasareaoprovedfouowinasmautrias.A
patiemtcohortof3000wilonly highlicht reactionshatoccur in morethan1in1000.The post-marketing
surveilanceoccursinphase4ofthecuinicattriat
@1MINENDOCRINE
